A Case of Severe Chronic Heart Failure Successfully Controlled with Long Term Administration of Tolvaptan; a V(2)-specific Vasopressin Receptor Antagonists

被引：0
|
作者：
Yamagami, Yuna [1 ]
Kinoshita, Hideyuki [1 ]
Kuwahara, Koichiro [1 ]
Kuwabara, Yoshihiro [1 ]
Yasuno, Shinji [2 ]
Usami, Satoru [1 ]
Nakagawa, Yasuaki [1 ]
Nishikimi, Toshio [1 ]
Ueshima, Kenji [2 ]
Nakao, Kazuwa [1 ]
机构：
[1] Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Kyoto, Japan
[2] Kyoto Univ, EBM Res Ctr, Kyoto, Japan
来源：
JOURNAL OF CARDIAC FAILURE | 2011年 / 17卷 / 09期
关键词：
D O I：
10.1016/j.cardfail.2011.06.565
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S166 / S166
页数：1
相关论文
共 50 条
  • [31] Vasopressin receptor antagonists in patients with chronic heart failure; [Vasopressinrezeptorantagonisten bei Patienten mit chronischer Herzinsuffizienz]
    De Vecchis R.
    Cantatrione C.
    Mazzei D.
    Herz, 2017, 42 (5) : 492 - 497
  • [32] Effects of an oral, nonpeptide, selective V-2 receptor vasopressin antagonist in patients with chronic heart failure
    Abraham, WT
    Oren, RM
    Crisman, TS
    Robertson, AD
    Shakar, S
    Lowes, BD
    Panther, L
    Kelley, P
    Pies, CJ
    Bristow, MR
    Schrier, RW
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 29 (02) : 7271 - 7271
  • [33] Safety and Efficacy of Long-Term Use of Tolvaptan in Patients With Heart Failure and Chronic Kidney Disease
    Uemura, Yusuke
    Shibata, Rei
    Takemoto, Kenji
    Uchikawa, Tomohiro
    Koyasu, Masayoshi
    Ishikawa, Shinji
    Imai, Ryo
    Ozaki, Yuta
    Watanabe, Takashi
    Teraoka, Tsubasa
    Watarai, Masato
    Murohara, Toyoaki
    CIRCULATION JOURNAL, 2017, 81 (11) : 1736 - +
  • [34] Chronic vasopressin V1A but not V2 receptor antagonism prevents heart failure in chronically infarcted rats
    Van Kerckhoven, R
    Lankhuizen, I
    van Veghel, R
    Saxena, PR
    Schoemaker, RG
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 449 (1-2) : 135 - 141
  • [35] THE RISK FACTORS OF WORSENING RENAL FUNCTION BY VASOPRESSIN RECEPTOR 2 ANTAGONIST (TOLVAPTAN) IN NON-DIALYSIS CHRONIC KIDNEY DISEASE PATIENTS WITH CHRONIC HEART FAILURE
    Koibuchi, Kiyoto
    Tanaka, Kentaro
    Aoki, Toshiyuki
    Miyagi, Moriatsu
    Sakai, Ken
    Aikawa, Atsushi
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 : 122 - 122
  • [36] Effects of specific angiotensin II receptor antagonists on exercise tolerance in chronic heart failure
    Ikram H.
    Heart Failure Reviews, 1999, 3 (3) : 217 - 220
  • [37] Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients With Symptomatic Heart Failure and Systolic Dysfunction An International, Multicenter, Randomized, Placebo-Controlled Trial
    Udelson, James E.
    Orlandi, Cesare
    Ouyang, John
    Krasa, Holly
    Zimmer, Christopher A.
    Frivold, Geir
    Haught, W. Herbert
    Meymandi, Sheiba
    Macarie, Cezar
    Raef, Dimitar
    Wedge, Patricia
    Konstam, Marvin A.
    Gheorghiade, Mihai
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (19) : 1540 - 1545
  • [38] Divergent long term effects of calcium antagonists in a rat model of chronic heart failure
    Mulder, P
    Richard, V
    Hogie, M
    Henry, JP
    Lallemand, F
    Thulliez, C
    CIRCULATION, 1997, 96 (08) : 2937 - 2937
  • [39] Diverging long term effects of calcium antagonists in a rat model of chronic heart failure
    Mulder, P
    Richard, V
    Hogie, M
    Henry, JP
    Lallemand, F
    Thuillez, C
    BRITISH JOURNAL OF PHARMACOLOGY, 1997, 122 : U115 - U115
  • [40] Vasopressin V2 receptor antagonist tolvaptan is effective in heart failure patients with reduced left ventricular systolic function and low blood pressure
    Suzuki, S.
    Yoshihisa, A.
    Abe, Y.
    Saito, T.
    Ohwada, T.
    Suzuki, H.
    Saitoh, S.
    Kubota, I.
    Takeishi, Y.
    EUROPEAN HEART JOURNAL, 2014, 35 : 160 - 161
12345